The Kile lab's research has focused primarily on the molecular regulation of blood cell formation and function, at steady state, and in disease settings such as inflammation and leukemia. We have a deep interest in the role programmed cell death pathways play in these processes, and how the cell death machinery mediates the response to pathophysiological insults such as cancer chemotherapy. Our work has contributed to understanding the survival of platelets – the tiny cells that mediate blood clotting – and informed the clinical development of a new class of cancer drugs called the BH3 mimetics. We have identified critical roles for the cell death machinery in suppressing innate immune signalling, suggesting new therapeutic approaches to the treatment of viral infections and cancer.